{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:41:55Z","timestamp":1774316515218,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11940-019-0593-y","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T05:26:42Z","timestamp":1569475602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pediatric Ocular Myasthenia Gravis"],"prefix":"10.1007","volume":"21","author":[{"given":"Kristen","family":"Fisher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veeral","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"issue":"10","key":"593_CR1","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1212\/WNL.42.10.1888","volume":"42","author":"LH Phillips","year":"1992","unstructured":"Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42(10):1888\u201393.","journal-title":"Neurology."},{"issue":"1","key":"593_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1055\/s-2004-829591","volume":"24","author":"PI Andrews","year":"2004","unstructured":"Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004;24(1):101\u201310.","journal-title":"Semin Neurol"},{"issue":"4","key":"593_CR3","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1542\/peds.2013-0814","volume":"132","author":"J Vanderpluym","year":"2013","unstructured":"Vanderpluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical characteristics of pediatric myasthenia: a surveillance study. Pediatrics. 2013;132(4):e939\u201344.","journal-title":"Pediatrics."},{"issue":"7","key":"593_CR4","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/S0161-6420(03)00460-3","volume":"110","author":"JH Kim","year":"2003","unstructured":"Kim JH, Hwang JM, Hwang YS, Kim KJ, Chae J. Childhood ocular myasthenia gravis. Ophthalmology. 2003;110(7):1458\u201362.","journal-title":"Ophthalmology."},{"issue":"4","key":"593_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ajo.2010.05.002","volume":"150","author":"SL Pineles","year":"2010","unstructured":"Pineles SL, Avery RA, Moss HE, et al. Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol. 2010;150(4):453\u2013459.e3.","journal-title":"Am J Ophthalmol"},{"key":"593_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pediatrneurol.2018.06.007","volume":"87","author":"K Vanikieti","year":"2018","unstructured":"\u2022\u2022 Vanikieti K, Lowwongngam K, Padungkiatsagul T, Visudtibhan A, Poonyathalang A. Juvenile ocular myasthenia gravis: presentation and outcome of a large cohort. Pediatr Neurol. 2018;87:36\u201341 A recent large cohort of juvenile patients with OMG is reported in this article, discussing symptom presentation and treatment outcomes.","journal-title":"Pediatr Neurol"},{"issue":"6","key":"593_CR7","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.athoracsur.2011.08.001","volume":"92","author":"Z Liu","year":"2011","unstructured":"Liu Z, Feng H, Yeung SC, et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg. 2011;92(6):1993\u20139.","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"593_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2014.12.006","volume":"52","author":"M Motobayashi","year":"2015","unstructured":"Motobayashi M, Inaba Y, Nishimura T, Kobayashi N, Nakazawa Y, Koike K. An increase in circulating B cell-activating factor in childhood-onset ocular myasthenia gravis. Pediatr Neurol. 2015;52(4):404\u20139.","journal-title":"Pediatr Neurol"},{"key":"593_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","volume":"77","author":"C Liu","year":"2017","unstructured":"\u2022\u2022 Liu C, Gui M, Cao Y, et al. Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone. Pediatr Neurol. 2017;77:42\u20137 Recent study published on the use of tacrolimus in 14 children with MG and its effectiveness.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"593_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ncl.2016.08.008","volume":"35","author":"SV Smith","year":"2017","unstructured":"\u2022 Smith SV, Lee AG. Update on ocular myasthenia gravis. Neurol Clin. 2017;35(1):115\u201323 Recent relevant review on OMG, diagnostic modalities, and treatment options.","journal-title":"Neurol Clin"},{"issue":"3","key":"593_CR11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0161-6420(99)00138-4","volume":"107","author":"P Mullaney","year":"2000","unstructured":"Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology. 2000;107(3):504\u201310.","journal-title":"Ophthalmology."},{"issue":"14","key":"593_CR12","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0883073816666206","volume":"31","author":"HN Lee","year":"2016","unstructured":"Lee HN, Kang HC, Lee JS, Kim HD, Shin HY, Kim SM, et al. Juvenile myasthenia gravis in Korea: subgroup analysis according to sex and onset age. J Child Neurol. 2016;31(14):1561\u20138.","journal-title":"J Child Neurol"},{"issue":"1","key":"593_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/CND.0b013e31821c5634","volume":"13","author":"MK Mittal","year":"2011","unstructured":"Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, et al. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis. 2011;13(1):46\u201352.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"7","key":"593_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ophtha.2007.10.022","volume":"115","author":"S Ortiz","year":"2008","unstructured":"Ortiz S, Borchert M. Long-term outcomes of pediatric ocular myasthenia gravis. Ophthalmology. 2008;115(7):1245\u20131248.e1.","journal-title":"Ophthalmology"},{"issue":"1","key":"593_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/WNO.0b013e318280d630","volume":"33","author":"JH Peragallo","year":"2013","unstructured":"Peragallo JH, Velez FG, Demer JL, Pineles SL. Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis. J Neuroophthalmol. 2013;33(1):40\u20134.","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"593_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00417-012-2227-x","volume":"251","author":"KA Park","year":"2013","unstructured":"Park KA, Oh SY. Treatment for diplopia in patients with myasthenia gravis. Graefes Arch Clin Exp Ophthalmol. 2013;251(3):895\u2013901.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"593_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00002341-200103000-00005","volume":"17","author":"EA Bradley","year":"2001","unstructured":"Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthalmic Plast Reconstr Surg. 2001;17(2):103\u201310.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"593_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/08820538.2017.1284871","volume":"33","author":"K Brogan","year":"2018","unstructured":"\u2022 Brogan K, Farrugia ME, Crofts K. Ptosis surgery in patients with myasthenia gravis: a useful adjunct to medical therapy. Semin Ophthalmol. 2018;33(3):429\u201334 A report of patients with persistent ptosis in MG who have undergone surgical correction and discussion of the benefits and outcome of the procedure.","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"593_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3109\/08820538.2015.1131835","volume":"32","author":"Michel J. Belliveau","year":"2016","unstructured":"\u2022 Belliveau MJ, Oestreicher JH. Ptosis repair in ocular myasthenia gravis. Semin Ophthalmol. 2017;32(5):564-8 Additional case series of patients with OMG and persistent ptosis who have undergone surgical repair and the outcomes related to the procedure.","journal-title":"Seminars in Ophthalmology"},{"issue":"9","key":"593_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.optm.2009.09.023","volume":"81","author":"JA Pruitt","year":"2010","unstructured":"Pruitt JA, Ilsen PF. On the frontline: what an optometrist needs to know about myasthenia gravis. Optometry. 2010;81(9):454\u201360.","journal-title":"Optometry."},{"issue":"1","key":"593_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00417-014-2847-4","volume":"253","author":"J Han","year":"2015","unstructured":"Han J, Han SY, Han SH, Lee JB. Strabismus surgery and long-term visual outcomes in patients with preadolescent onset ocular myasthenia gravis. Graefes Arch Clin Exp Ophthalmol. 2015;253(1):157\u201363.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"593_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","volume":"21","author":"E Kerty","year":"2014","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS\/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687\u201393.","journal-title":"Eur J Neurol"},{"issue":"5\u20136","key":"593_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43(5\u20136):428\u201335.","journal-title":"Autoimmunity"},{"issue":"2","key":"593_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pediatrneurol.2012.07.008","volume":"48","author":"CM Ionita","year":"2013","unstructured":"Ionita CM, Acsadi G. Management of juvenile myasthenia gravis. Pediatr Neurol. 2013;48(2):95\u2013104.","journal-title":"Pediatr Neurol"},{"issue":"8","key":"593_CR25","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.braindev.2008.08.016","volume":"31","author":"K Ishigaki","year":"2009","unstructured":"Ishigaki K, Shishikura K, Murakami T, Suzuki H, Hirayama Y, Osawa M. Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis. Brain Dev. 2009;31(8):634\u20137.","journal-title":"Brain Dev"},{"issue":"2","key":"593_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nmd.2011.08.007","volume":"22","author":"TL Ware","year":"2012","unstructured":"Ware TL, Ryan MM, Kornberg AJ. Autoimmune myasthenia gravis, immunotherapy and thymectomy in children. Neuromuscul Disord. 2012;22(2):118\u201321.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"593_CR27","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jpedsurg.2015.12.016","volume":"51","author":"A Ashfaq","year":"2016","unstructured":"\u2022 Ashfaq A, Bernes SM, Weidler EM, Notrica DM. Outcomes of thoracoscopic thymectomy in patients with juvenile myasthenia gravis. J Pediatr Surg. 2016;51(7):1078\u201383 A relevant case series on outcomes of patients with MG who have undergone thymectomy and discussion of efficacy of thymectomy.","journal-title":"J Pediatr Surg"},{"issue":"6","key":"593_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00383-010-2837-5","volume":"27","author":"IA Hennessey","year":"2011","unstructured":"Hennessey IA, Long AM, Hughes I, Humphrey G. Thymectomy for inducing remission in juvenile myasthenia gravis. Pediatr Surg Int. 2011;27(6):591\u20134.","journal-title":"Pediatr Surg Int"},{"issue":"5","key":"593_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00383-019-04441-0","volume":"35","author":"AG Kim","year":"2019","unstructured":"\u2022\u2022 Kim AG, Upah SA, Brandsema JF, Yum SW, Blinman TA. Thoracoscopic thymectomy for juvenile myasthenia gravis. Pediatr Surg Int. 2019;35(5):603\u201310 Most recent and largest cohort of juvenile patients who have undergone thymectomy, discussion of outcomes and evidence relating to efficacy of the procedure.","journal-title":"Pediatr Surg Int"},{"issue":"10","key":"593_CR30","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10072-017-3058-7","volume":"38","author":"K Zhu","year":"2017","unstructured":"\u2022\u2022 Zhu K, Li J, Huang X, et al. Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis. Neurol Sci. 2017;38(10):1753\u201360 This article specifically discusses the outcomes of patients with OMG who have undergone thymectomy, review of literature, and review of patients.","journal-title":"Neurol Sci"},{"issue":"7","key":"593_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00383-019-04486-1","volume":"35","author":"Michael A. Catalano","year":"2019","unstructured":"\u2022\u2022 Catalano MA, Mullan CW, Rich BS, Glick RD. Pediatric thymectomy: a study of national trends in demographics, short-term outcomes, and cost. Pediatr Surg Int. 2019;35(7):749\u201357.A cross-sectional analysis looking at thymectomy in the pediatric population, safety, and outcomes with the procedure.","journal-title":"Pediatric Surgery International"},{"issue":"2","key":"593_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/acs.2019.02.02","volume":"8","author":"E Kaba","year":"2019","unstructured":"Kaba E, Cosgun T, Ayalp K, Toker A. Robotic thymectomy for myasthenia gravis. Ann Cardiothorac Surg. 2019;8(2):288\u201391.","journal-title":"Ann Cardiothorac Surg"},{"issue":"1","key":"593_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0887-8994(99)00112-5","volume":"22","author":"D Selcen","year":"2000","unstructured":"Selcen D, Dabrowski ER, Michon AM, Nigro MA. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol. 2000;22(1):40\u20133.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"593_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","volume":"143","author":"ME Wylam","year":"2003","unstructured":"Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr. 2003;143(5):674\u20137.","journal-title":"J Pediatr"},{"key":"593_CR35","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.4076\/1757-1626-2-6609","volume":"2","author":"N Tzaribachev","year":"2009","unstructured":"Tzaribachev N, Koetter I, Kuemmerle-deschner JB, Schedel J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J. 2009;2:6609.","journal-title":"Cases J"},{"issue":"3","key":"593_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/mus.21521","volume":"41","author":"N Zebardast","year":"2010","unstructured":"Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. 2010;41(3):375\u20138.","journal-title":"Muscle Nerve"},{"issue":"3","key":"593_CR37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367\u201376.","journal-title":"Drugs."},{"issue":"1","key":"593_CR38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mus.26512","volume":"60","author":"C Edmundson","year":"2019","unstructured":"Edmundson C, Guidon AC. Eculizumab: a complementary addition to existing long-term therapies for myasthenia gravis. Muscle Nerve. 2019;60(1):7\u20139.","journal-title":"Muscle Nerve"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0593-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-019-0593-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0593-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T22:17:06Z","timestamp":1695248226000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-019-0593-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1007\/s11940-019-0593-y","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]},"assertion":[{"value":"26 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"46"}}